According to Sinopharm's latest financial reports the company's current earnings are HK$80.05 Billion. In 2022 the company made an earning of HK$24.89 Billion a decrease over its 2021 earnings that were of HK$25.32 Billion. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | HK$18.70 B | -24.87% |
2022 | HK$24.89 B | -1.72% |
2021 | HK$25.32 B | 11.7% |
2020 | HK$22.67 B | 18.44% |
2019 | HK$19.14 B | 10.85% |
2018 | HK$17.27 B | 3.05% |
2017 | HK$16.75 B | 36.48% |
2016 | HK$12.27 B | 7.11% |
2015 | HK$11.46 B | 12.38% |
2014 | HK$10.20 B | 25.05% |
2013 | HK$8.15 B | 22.54% |
2012 | HK$6.65 B | 35.43% |
2011 | HK$4.91 B | 52.24% |
2010 | HK$3.22 B | 30.99% |
2009 | HK$2.46 B | 60.59% |
2008 | HK$1.53 B | 48.29% |
2007 | HK$1.03 B | 123.29% |
2006 | HK$0.46 B |